Informace o publikaci

Complex analysis of the p53 tumor suppressor in lung carcinoma

Název česky Komplexní analýza nádorového supresoru p53 u plicního karcinomu
Autoři

ŠMARDOVÁ Jana LIŠKOVÁ Květoslava RAVČUKOVÁ Barbora MALČÍKOVÁ Jitka HAUSNEROVÁ Jitka SVITÁKOVÁ Miluše HRABÁLKOVÁ Renata ZLÁMALÍKOVÁ Lenka STAŇO KOZUBÍK Kateřina BLAHÁKOVÁ Ivona ŠPELDOVÁ Jana JARKOVSKÝ Jiří ŠMARDA Jan

Rok publikování 2016
Druh Článek v odborném periodiku
Časopis / Zdroj Oncology Reports
Fakulta / Pracoviště MU

Přírodovědecká fakulta

Citace
Doi http://dx.doi.org/10.3892/or.2015.4533
Obor Genetika a molekulární biologie
Klíčová slova lung adenocarcinoma; p53 tumor suppressor; FASAY; FISH; TP53 mutation
Popis Lung cancer is the leading cause of cancer-related deaths worldwide. Mutations of the TP53 gene occur very frequently in lung carcinomas and they play an important role in both oncogenic transformation of lung epithelial cells and lung carcinoma progression. We determined the TP53 status in 42 samples of squamous cell lung carcinoma (SQCC) and 56 samples of lung adenocarcinoma (AC) by the functional analysis FASAY and its variant called split assay. Altogether, we detected 64 TP53 mutations in 63 patients and analyzed them by cDNA and gDNA sequencing. The TP53 mutations were found in 76.2% (32/42) of SQCC cases, and 55.4% (31/56) of ACs. Immunoblotting revealed the p53 protein accumulation in 18 samples (42.9%) among SQCC cases and 19 samples (33.9%) among AC cases. Using fluorescence in situ hybridization we detected loss of the TP53-specific 17p13.3 locus in 23 from 41 analyzed SQCC samples (56.1%) and in 20 from 54 analyzed AC samples (37.0%). We did not find any statistically significant differences in overall and disease-free survival in relation to TP53 status.

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info